Active	Status	Sponsor type	Region	Phase	Filter
4 Active 5 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Weiyong
NCT04673474: A Food-Effect Study of Hemay022 in Healthy Participants	Recruiting	1	12	RoW	Hemay022	Tianjin Hemay Oncology Pharmaceutical Co., Ltd	Food-drug Interaction	02/21	05/21
NCT06376474: To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage	Recruiting	1	24	RoW	Hemay005, Hemay005 tablet	Ganzhou Hemay Pharmaceutical Co., Ltd	Psoriasis	12/24	12/24
NCT06380153: To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment	Recruiting	1	24	RoW	Hemay005, Hemay005 tablet	Ganzhou Hemay Pharmaceutical Co., Ltd	Psoriasis	12/24	12/24
NCT06111196: Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects	Completed	1	59	RoW	Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection, BAT3306 injection, Pembrolizumab injection, KEYTRUDA® (EU-sourced)	Bio-Thera Solutions, Wuhan Union Hospital, China	Healthy Male Subjects	06/24	06/24